Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 7;103(6):772-5.
doi: 10.1038/sj.bjc.6605828. Epub 2010 Aug 24.

Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients

A Mailliez  1 , C Baldini, J T Van, V Servent, Y Mallet, J Bonneterre
Affiliations

Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients

A Mailliez et al. Br J Cancer. .

Abstract

Background: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of nasal septum perforations have been reported. We report our experience of nasal perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the metastatic settings.

Methods: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded according to CTCAE.

Results: Five nasal septum perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15 mg kg(-1) 3 weekly. Three pts were metastatic. Bevacizumab was associated with docetaxel (100 mg m(-2) every 3 weeks) in two pts and with weekly paclitaxel in one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two cases, nasal septum perforation occurred at the time of docetaxel treatment.

Conclusion: A high incidence of nasal septum perforation has been shown in pts with breast cancer receiving bevacizumab together with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Nasal septum perforation.
Figure 2
Figure 2
Nasal septum irritation.
See this image and copyright information in PMC

References

    1. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2(11): 1843–1849 - PubMed
    1. Brufsky A, Bondarenko I, Smirnov V, Hurvitz S, Perez E, Ponomarova O, Vynnychenko I, Swamy R, Mu H, Rivera R (2009) RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. Cancer Res 69(24 suppl): 495s. (abst 42) - PubMed
    1. Burkart CM, Grisel JJ, Hom DB (2008) Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope 118(9): 1539–1541 - PubMed
    1. Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS 31 March 2003 (http://ctep.cancer.gov), Published on 9 August 2006
    1. Fakih MG, Lombardo JC (2006) Bevacizumab-induced nasal septum perforation. Oncologist 11(1): 85–86 - PubMed